The role of different immunocompetent cell populations in the pathogenesis of head and neck cancer—regulatory mechanisms of pro-and anti-cancer activity and their …
K Starska-Kowarska - Cancers, 2023 - mdpi.com
Simple Summary According to the latest GLOBOCAN data, head and neck squamous cell
carcinoma (HNSCC) represents the sixth most prevalent human malignancy. Recent studies …
carcinoma (HNSCC) represents the sixth most prevalent human malignancy. Recent studies …
HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma
N Coleman, KL Marcelo, JF Hopkins, NI Khan… - JCO Precision …, 2023 - ascopubs.org
PURPOSE In head and neck squamous cell carcinoma (HNSCC), HRAS mutation is a new
actionable oncogene driver. We aimed to evaluate HRAS mutational variants, comutation …
actionable oncogene driver. We aimed to evaluate HRAS mutational variants, comutation …
The EXTREME regimen associating cetuximab and cisplatin favors head and neck cancer cell death and immunogenicity with the induction of an anti-cancer immune …
J De Azevedo, J Mourtada, C Bour, V Devignot… - Cells, 2022 - mdpi.com
(1) Background: The first line of treatment for recurrent/metastatic Head and Neck Squamous
Cell Carcinoma (HNSCC) has recently evolved with the approval of immunotherapies that …
Cell Carcinoma (HNSCC) has recently evolved with the approval of immunotherapies that …
A novel CXCR4-targeted diphtheria toxin nanoparticle inhibits invasion and metastatic dissemination in a head and neck squamous cell carcinoma mouse model
E Rioja-Blanco, A Gallardo, I Arroyo-Solera, P Álamo… - Pharmaceutics, 2022 - mdpi.com
Loco-regional recurrences and metastasis represent the leading causes of death in head
and neck squamous cell carcinoma (HNSCC) patients, highlighting the need for novel …
and neck squamous cell carcinoma (HNSCC) patients, highlighting the need for novel …
Skin Toxicity as a Predictor of Survival in Metastatic Colorectal Cancer Patients Treated with Anti-EGFR: Fact or Fallacy?
TY Chiang, HC Hsu, YJ Chern, CK Liao, YJ Hsu… - Cancers, 2023 - mdpi.com
Simple Summary Targeted therapy and chemotherapy are the mainstays of treatment to
improve the survival of patients with metastatic colorectal cancer (mCRC). When RAS and …
improve the survival of patients with metastatic colorectal cancer (mCRC). When RAS and …
[HTML][HTML] The efficacy of cetuximab plus PD-1 inhibitors as salvage therapy in PD-1 refractory patients with recurrent or metastatic head and neck squamous cell …
R Hui, X Liu, Z Fan, H Ji, D Wei, G Ren - Journal of Cancer, 2024 - ncbi.nlm.nih.gov
Purpose: The prognosis of patients with recurrent or metastatic head and neck squamous
cell carcinoma (R/M HNSCC) that are refractory to programmed cell death protein 1 (PD-1) …
cell carcinoma (R/M HNSCC) that are refractory to programmed cell death protein 1 (PD-1) …
Revisiting EXTREME in the Immuno-Oncology Era: How to Improve Its Outcomes
P Szturz, JB Vermorken - The Oncologist, 2021 - academic.oup.com
The choice of first-line palliative treatment has always been one of the crucial decisions in
the management of patients with recurrent and/or metastatic squamous cell carcinoma of the …
the management of patients with recurrent and/or metastatic squamous cell carcinoma of the …
First‑line programmed cell death 1 inhibitor plus chemotherapy vs. standard treatment in patients with recurrent or metastatic oral squamous cell carcinoma: A …
L Cheng, C Chai, Y Liu, J Jiao - Oncology Letters, 2024 - spandidos-publications.com
Abstract Programmed cell death 1 (PD‑1) inhibitor revives the killing effect of immune cells to
prevent tumor progression. The present study aimed to evaluate the efficacy and safety of …
prevent tumor progression. The present study aimed to evaluate the efficacy and safety of …
[HTML][HTML] 同步放化疗治疗局部晚期喉癌的适应证探讨
王文静， 皇甫辉， 侯彦杰， 冯彦， 张春明… - Journal of Clinical …, 2022 - ncbi.nlm.nih.gov
喉癌是头颈部常见的恶性肿瘤之一， 美国国立综合癌症网络(NCCN) 临床实践指南认为同步放
化疗是局部晚期喉癌最有效的器官保护策略， 可在不降低患者生存率的前提下保留患者喉部 …
化疗是局部晚期喉癌最有效的器官保护策略， 可在不降低患者生存率的前提下保留患者喉部 …
[PDF][PDF] Adverse event management as a pathway to optimal outcomes in head and neck squamous cell carcinoma patients: A clinical case
VD Sanikovich, MI Sekacheva, EV Orlova… - Consilium …, 2024 - consilium.orscience.ru
Squamous cell carcinoma of the head and neck is the sixth most common cancer worldwide.
However, malignant tumors of the middle ear are extremely rare. Squamous cell carcinoma …
However, malignant tumors of the middle ear are extremely rare. Squamous cell carcinoma …